Newsroom
Jump to:
Press Releases
January 21, 2026
Truvian Health Receives another FDA Clearance – for Complete Blood Count (CBC) on TruVerus™
FDA Clearance of CBC Marks a Defining Platform Milestone, Expanding TruVerus™ to 26 Cleared Assays and the first FDA clearance for CBC from a lithium heparin sample.
January 12, 2026
Truvian Health Rapidly Expands TruVerus™ Menu with FDA Clearances for Cardiovascular, Liver, and Core Metabolic Health Tests
Truvian announced it has received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.
January 7, 2026
Truvian Appoints Renowned Physician-Scientist and Diagnostic Innovator Dr. Michael Mina as Chief Medical and Strategy Officer
Truvian today announced the appointment of Michael J. Mina, MD, PhD as Chief Medical and Strategy Officer to oversee clinical and regulatory strategy, while advancing strategic partnerships and opportunities.
